Clinical Trial Update: Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis [Phase 3]

View source ↗

Summary

Phase 3 trial update on oral once-daily vonoprazan (TAK-438) for erosive esophagitis reports efficacy and safety data; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erosive Esophagitis

Drugs mentioned

• Vonoprazan (vonoprazan)

Snippet

Sponsor: Takeda | Conditions: Erosive Esophagitis | Phase 3 | Status: COMPLETED | Results posted: 2019-06-03